RG6496

Phase 1Small molecule

Roche

RG6496 is one of 3 small molecule programs targeting Huntington's Disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Huntington's DiseaseActive, not recruiting

Huntington's DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Huntington's Disease

#DrugCompanyPhaseTrials

Ingrezza

Neurocrine Biosciences

Austedo

2 3

RG6496

Roche

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Huntington's Disease

NCT07246941

Clinical

Trials by Indication[1]

Huntington's Disease1 trial

A Phase I, 2-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-ascending Doses of Intrathecally Administered RG6496 in a Randomized, Placebo-controlled, Investigator/Participant-blind Study With an Open-label Extension in Huntington's Disease Gene Expansion Carriers

Active, not recruiting· Roche logo

Roche·Phase 1·NCT07246941·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RG6496. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RG6496 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RG6496. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Roche

RG6496

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Huntington's Disease1 trial

References

Drug Info

Quick Facts

Related News